Cargando…
Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders
Extracellular vesicles (EVs) have been recognized as promising candidates for developing novel therapeutics for a wide range of pathologies, including ocular disorders, due to their ability to deliver a diverse array of bioactive molecules, including proteins, lipids, and nucleic acids, to recipient...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219002/ https://www.ncbi.nlm.nih.gov/pubmed/37240353 http://dx.doi.org/10.3390/ijms24109006 |
_version_ | 1785048906808164352 |
---|---|
author | Massoumi, Hamed Amin, Sohil Soleimani, Mohammad Momenaei, Bita Ashraf, Mohammad Javad Guaiquil, Victor H. Hematti, Peiman Rosenblatt, Mark I. Djalilian, Ali R. Jalilian, Elmira |
author_facet | Massoumi, Hamed Amin, Sohil Soleimani, Mohammad Momenaei, Bita Ashraf, Mohammad Javad Guaiquil, Victor H. Hematti, Peiman Rosenblatt, Mark I. Djalilian, Ali R. Jalilian, Elmira |
author_sort | Massoumi, Hamed |
collection | PubMed |
description | Extracellular vesicles (EVs) have been recognized as promising candidates for developing novel therapeutics for a wide range of pathologies, including ocular disorders, due to their ability to deliver a diverse array of bioactive molecules, including proteins, lipids, and nucleic acids, to recipient cells. Recent studies have shown that EVs derived from various cell types, including mesenchymal stromal cells (MSCs), retinal pigment epithelium cells, and endothelial cells, have therapeutic potential in ocular disorders, such as corneal injury and diabetic retinopathy. EVs exert their effects through various mechanisms, including promoting cell survival, reducing inflammation, and inducing tissue regeneration. Furthermore, EVs have shown promise in promoting nerve regeneration in ocular diseases. In particular, EVs derived from MSCs have been demonstrated to promote axonal regeneration and functional recovery in various animal models of optic nerve injury and glaucoma. EVs contain various neurotrophic factors and cytokines that can enhance neuronal survival and regeneration, promote angiogenesis, and modulate inflammation in the retina and optic nerve. Additionally, in experimental models, the application of EVs as a delivery platform for therapeutic molecules has revealed great promise in the treatment of ocular disorders. However, the clinical translation of EV-based therapies faces several challenges, and further preclinical and clinical studies are needed to fully explore the therapeutic potential of EVs in ocular disorders and to address the challenges for their successful clinical translation. In this review, we will provide an overview of different types of EVs and their cargo, as well as the techniques used for their isolation and characterization. We will then review the preclinical and clinical studies that have explored the role of EVs in the treatment of ocular disorders, highlighting their therapeutic potential and the challenges that need to be addressed for their clinical translation. Finally, we will discuss the future directions of EV-based therapeutics in ocular disorders. Overall, this review aims to provide a comprehensive overview of the current state of the art of EV-based therapeutics in ophthalmic disorders, with a focus on their potential for nerve regeneration in ocular diseases. |
format | Online Article Text |
id | pubmed-10219002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102190022023-05-27 Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders Massoumi, Hamed Amin, Sohil Soleimani, Mohammad Momenaei, Bita Ashraf, Mohammad Javad Guaiquil, Victor H. Hematti, Peiman Rosenblatt, Mark I. Djalilian, Ali R. Jalilian, Elmira Int J Mol Sci Review Extracellular vesicles (EVs) have been recognized as promising candidates for developing novel therapeutics for a wide range of pathologies, including ocular disorders, due to their ability to deliver a diverse array of bioactive molecules, including proteins, lipids, and nucleic acids, to recipient cells. Recent studies have shown that EVs derived from various cell types, including mesenchymal stromal cells (MSCs), retinal pigment epithelium cells, and endothelial cells, have therapeutic potential in ocular disorders, such as corneal injury and diabetic retinopathy. EVs exert their effects through various mechanisms, including promoting cell survival, reducing inflammation, and inducing tissue regeneration. Furthermore, EVs have shown promise in promoting nerve regeneration in ocular diseases. In particular, EVs derived from MSCs have been demonstrated to promote axonal regeneration and functional recovery in various animal models of optic nerve injury and glaucoma. EVs contain various neurotrophic factors and cytokines that can enhance neuronal survival and regeneration, promote angiogenesis, and modulate inflammation in the retina and optic nerve. Additionally, in experimental models, the application of EVs as a delivery platform for therapeutic molecules has revealed great promise in the treatment of ocular disorders. However, the clinical translation of EV-based therapies faces several challenges, and further preclinical and clinical studies are needed to fully explore the therapeutic potential of EVs in ocular disorders and to address the challenges for their successful clinical translation. In this review, we will provide an overview of different types of EVs and their cargo, as well as the techniques used for their isolation and characterization. We will then review the preclinical and clinical studies that have explored the role of EVs in the treatment of ocular disorders, highlighting their therapeutic potential and the challenges that need to be addressed for their clinical translation. Finally, we will discuss the future directions of EV-based therapeutics in ocular disorders. Overall, this review aims to provide a comprehensive overview of the current state of the art of EV-based therapeutics in ophthalmic disorders, with a focus on their potential for nerve regeneration in ocular diseases. MDPI 2023-05-19 /pmc/articles/PMC10219002/ /pubmed/37240353 http://dx.doi.org/10.3390/ijms24109006 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Massoumi, Hamed Amin, Sohil Soleimani, Mohammad Momenaei, Bita Ashraf, Mohammad Javad Guaiquil, Victor H. Hematti, Peiman Rosenblatt, Mark I. Djalilian, Ali R. Jalilian, Elmira Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders |
title | Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders |
title_full | Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders |
title_fullStr | Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders |
title_full_unstemmed | Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders |
title_short | Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders |
title_sort | extracellular-vesicle-based therapeutics in neuro-ophthalmic disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219002/ https://www.ncbi.nlm.nih.gov/pubmed/37240353 http://dx.doi.org/10.3390/ijms24109006 |
work_keys_str_mv | AT massoumihamed extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders AT aminsohil extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders AT soleimanimohammad extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders AT momenaeibita extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders AT ashrafmohammadjavad extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders AT guaiquilvictorh extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders AT hemattipeiman extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders AT rosenblattmarki extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders AT djalilianalir extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders AT jalilianelmira extracellularvesiclebasedtherapeuticsinneuroophthalmicdisorders |